Science: News

Precel

  1. We are presenting the results of our research at the European Society for Medical Oncology (ESMO) (5/15/2014) - Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: “Preclinical evaluation of a novel, selective …
  2. Celon Pharma S.A. research results on European Respiratory Society Congress (5/5/2014) - Celon Pharma S.A. researchers will attend ERS Annual Congress  that will be held from 6th to 10th of September 2014 in Munich. We will take this opportunity to present the latest data on innovative small-molecule inhibitors of JAK/STAT pathway and PI3Kd kinase which are being developed in our laboratories as …
  3. We are going to present our results on Alzheimer’s Association International Conference (4/14/2014) - Celon Pharma S.A. is going to present the latest data on proprietary innovative phosphodiesterase 9 inhibitors at AAIC in Copenhagen that is scheduled from 12th to 17th of July 2014. Conference attendees are welcome to visit our researchers at the poster entitled: “Characterization of a novel group of phosphodiesterase 9A …
  4. Results of Celon Pharma S.A. research at the European Hematology Congress (4/11/2014) - The 19th Congress of the European Hematology Association, during which Celon Pharma S.A. will be presenting the latest results of research on developing innovative PI3K-delta inhibitors, will be held on 12-15 June in Milan. We wish to encourage participants to see our poster presentation entitled: “Preclinical evaluation of a novel …
  5. A new publication from Celon Pharma S.A. laboratories! (3/31/2014) - Our new publication on experimental oncology has just appeared! The article entitled “Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.” by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via …
  6. We are presenting the results of our research at the ECC in Amsterdam (9/28/2013) - Celon Pharma S.A. will participate in The European Cancer Congress 2013, which will be held in Amsterdam, the Netherlands. We will be presenting two posters at a session which is taking place on 29 September 2013: “Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line” and “Design …
  7. The first edition of the “Aim for Innovations” competition initiated by Celon Pharma S.A. was just launched (5/14/2013) - Press release Warsaw, May 2013 Celon Pharma S.A. announces a competition for research projects in the field of asthma and COPD. Aim for Innovations is a nationwide competition which is a call for cooperation with industry directed at outstanding scientists in the fields of medical science, pharmaceutics, biology and biotechnology …
  8. Results of Celon’s anti-Alzheimer’s drug research on AD/PD 2013 (2/27/2013) - Celon Pharma S.A. will present the results of one of its R&D projects focused on development of novel drugs for Alzheimer’s disease on The 11th International Conference on Alzheimer’s & Parkinson’s Diseases, Florence, Italy. Poster entitled: “Discovery of Novel GSK3beta Inhibitor Lead Structure Using Sequential Virtual Screening” will be displayed …
  9. We are at the EACR in Barcelona (7/7/2012) - You can meet us at the The European Association for Cancer Research conference in Barcelona (7-10 July), where we present the results of our studies: NPM-ALK I1171T mutation confers resistance to crizotinib in anaplastic large cell lymphoma. Differential gene transcription response to the treatment with JAK2 inhibitors – Ruxolitinib, SAR302503 …
  10. Celon Pharma received the Polish Agency for Enterprise Development (PARP)’s award for the most innovative project (5/17/2012) - On 15 May this year, the official award ceremony in a competition organised by the Polish Agency for Enterprise Development in cooperation with the Polish Society for Supporting Entrepreneurship took place. The goal of the competition was to honour modern and innovative business solutions. Celon Pharma received the main award …
  11. Celon Pharma on MKNOL (5/10/2012) - Celon Pharma is going to present on  VIII Multidisciplinary Conference on Drug Science (MKNOL) in Hotel Ossa & Spa near Rawa Mazowiecka. We’ve prepared two lectures: CPL-200-075, a novel potent renal sodium-glucose cotransporter 2 (SGLT2) inhibitor and Design and development of CPL-407-22 – novel, potent and selective JAK2 protein kinase inhibitor.
  12. Visit our booth on Bio-Forum 2012! (4/30/2012) - You are welcome to visit our booth on Bio-Forum – the biggest international event for bio-tech society in Central Europe (Brno, 23-24.05.2012)! We will be happy to meet you and to share with you information on Celon Pharma activities.
  13. We have launched a Computer-assisted Drug Design Lab (4/2/2012) - We have launched a Computer-assisted Drug Design Department. The unit’s task will be to support, in terms of bioinformatics and chemoinformatics, the process of designing active substances: developing methodology, conducting and analysing virtual screening, analysing the binding of active particles with proteins, estimating and assessing ADMET parameters, creating QSAR models. …
  14. Dr. Jacek Jaworski’s lecture in Celon Pharma (1/13/2012) - Dr.  Jacek Jaworski (Head of  Laboratory of Molecular and Cellular Neurobiology, International Institute of Molecular and Cell Biology in Warsaw) presented  in Celon Pharma the lecture entitled   „mTOR kinase in physiology and neuropathology”.